Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 269

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 269
---
 described below (the “IPO”), and subsequent to the IPO identifying a target company for a Business Combination. The Company will not generate any operating revenues until after the completion of its initial Business Combination, at the earliest. The Company generates non-operating income in the form of interest income on cash and cash equivalents from the proceeds derived from the IPO and unrealized gains and losses and the change in fair value of its warrants. The Company’s sponsor is Iris Acquisition Holdings LLC (formerly known as Tribe Arrow Holdings I LLC), a Delaware limited liability company (the “Sponsor”). The registration statement for the Company’s IPO was declared effective on March 4, 2021 (the “Effective Date”). On March 9, 2021, the Company consummated the IPO of 27,600,000 units (the “Units”), which included the full exercise by the underwriters of the over-allotment option to purchase an additional 3,600,000 Units, at $ 10.00 per Unit, generating gross proceeds of $ 276,000,000 , which is discussed in Note 3. Simultaneously with the closing of the IPO, the Company consummated the sale of 5,013,333 warrants (the “Private Warrants”) to the Sponsor and Cantor Fitzgerald & Co. (“Cantor”), the representative of the underwriters of the IPO, at a price of $ 1.50 per Private Warrant, generating gross proceeds of $ 7,520,000 , which is discussed in Note 4. Each warrant (including the Private Warrants and the warrants included as part of the Units) entitles the holder to purchase one share of common stock at a price of $ 11.50 per share. Transaction costs for the IPO amounting to $ 15,627,893 (consisting of $ 5,520,000 of underwriting discount, $ 9,660,000 of deferred underwriting discount, and $ 447,893 of other offering costs) were recognized, of which $ 606,622 was (i) allocated to the public warrants and Private Warrants and (ii) included in the statements of operations, and $ 15,021,271 was charged directly to stockholders’ equity. Following the closing of the IPO on March 9, 2021, $ 276,000,000 (approximately $ 10.00 per Unit) from the net proceeds of the sale of the Units in the IPO, including the proceeds